Immuron Limited advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.
In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub – bringing content and communication into a single integrated platform. The Company will also be regularly uploading new content via the hub, including videos accompanying select announcements, educational material, interviews and corporate research.
Chief Executive Officer, Steven Lydeamore, commented: “With a number of near term milestones coming up, there has never been a better time to launch an initiative to improve our communication with shareholders and the investment community. During the remainder of this calendar year Immuron anticipates submission and approval by the FDA of IMM-529 Investigational New Drug (IND) submission and topline results released by the Uniformed Services University for the Travelan® (IMM-124E) clinical trial.”
Read More: From Cold Calls to AI – How SalesTech is Rewriting the Sales Playbook
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Read More: SalesTechStar Interview with Luca Filardo, Chief Revenue Officer at Adlook
